Gastric Cancer
For registered Hong Kong doctors
OncologyRefining HER2 IHC Assessment Guided by CAP Reporting Template: Enabling Accurate Classification Across Solid Tumors and Addressing Intratumoral HeterogeneityThe use of IHC staining of tissue samples to guide targeted treatment is widely used in clinical practice, and is recommended by expert groups for many tumor types and biomarkers. The classical approach to IHC scoring for biomarkers, such as human epidermal growth factor receptor-2 (HER2), classifies specimens as either ‘positive’ or ‘negative’, scoring samples as IHC0, 1+, 2+ or 3+ per pathologists’ visual interpretation.
OncologyDecoding HER2 IHC Scoring Guidelines: Understanding Immunohistochemistry Scoring in Different CancersHuman Epidermal Growth Factor Receptor 2 (HER2) aberrations, such as overexpression, HER2 gene amplification, and HER2 mutations, have been extensively researched and are associated with tumor proliferation in various solid tumor types including breast cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, biliary tract cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and bladder cancer.1 The presence of HER2 aberrations is linked to reduced survival, increased chance of brain metastasis, and treatment resistance.2
HER2 as a biomarker in cancersHuman epidermal growth factor receptor-2 (HER2) is a member of the erythroblastic oncogene B (ERBB) family of transmembrane tyrosine kinase receptors that also includes epidermal growth factor receptor (EGFR, also known as HER1), and human epidermal growth factor receptors -3 and -4 (HER3, HER4).1,2 Despite being a receptor, HER2 has no known ligand, but its conformation is similar to the ligand-activated form of other ERBB family members, favoring heterodimerization with them.1,3
